ReviewProtein & cell2018
The dark side of browning.
Review in Protein & cell, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Uromodulin: A Novel Regulator of the Kidney-Adipose Axis in Diabetic Kidney Disease.International journal of molecular sciences · 2026Article
- Cancer cachexia: molecular basis and therapeutic advances.Signal transduction and targeted therapy · 2026Review
- Two Regions with Different Expression of Lipogenic Enzymes in Rats' Posterior Subcutaneous Fat Depot.International journal of molecular sciences · 2024Article
- Beyond the Cold: Activating Brown Adipose Tissue as an Approach to Combat Obesity.Journal of clinical medicine · 2024Review
- The Role of NADBiomedicines · 2023Review
- Evidence of Metabolic Dysfunction in Amyotrophic Lateral Sclerosis (ALS) Patients and Animal Models.Biomolecules · 2023Review
- Adipose-targeted triiodothyronine therapy counteracts obesity-related metabolic complications and atherosclerosis with negligible side effects.Nature communications · 2022Article
- SIRT7 suppresses energy expenditure and thermogenesis by regulating brown adipose tissue functions in mice.Nature communications · 2022Article
- Molecular and Physiological Effects of Browning Agents on White Adipocytes from Bone Marrow Mesenchymal Stromal Cells.International journal of molecular sciences · 2022Article
- Browning of the white adipose tissue regulation: new insights into nutritional and metabolic relevance in health and diseases.Nutrition & metabolism · 2022Review
- Cardiac ischemia modulates white adipose tissue in a depot-specific manner.Frontiers in physiology · 2022Article
- Strategies for Browning Agent Delivery.Pharmaceutical research · 2021Review
- Downregulation of SUV39H1 and CITED2 Exerts Additive Effect on Promoting Adipogenic Commitment of Human Mesenchymal Stem Cells.Stem cells and development · 2021Article
- Article
- miRNAs and Novel Food Compounds Related to the Browning Process.International journal of molecular sciences · 2019Review
- Metformin prevents the pathological browning of subcutaneous white adipose tissue.Molecular metabolism · 2019Article
- Review
- Regulation of Energy Expenditure and Brown/Beige Thermogenic Activity by Interleukins: New Roles for Old Actors.International journal of molecular sciences · 2018Review
- HDAC11 suppresses the thermogenic program of adipose tissue via BRD2.JCI insight · 2018Article
- A Western diet-induced mouse model reveals a possible mechanism by which metformin decreases obesity.European journal of clinical pharmacology · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
The induction of brown-like adipocyte development in white adipose tissue (WAT) confers numerous metabolic benefits by decreasing adiposity and increasing energy expenditure. Therefore, WAT browning has gained considerable attention for its potential to reverse obesity and its associated co-morbidities. However, this perspective has been tainted by recent studies identifying the detrimental effects of inducing WAT browning. This review aims to highlight the adverse outcomes of both overactive and underactive browning activity, the harmful side effects of browning agents, as well as the molecular brake-switch system that has been proposed to regulate this process. Developing novel strategies that both sustain the metabolic improvements of WAT browning and attenuate the related adverse side effects is therefore essential for unlocking the therapeutic potential of browning agents in the treatment of metabolic diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.